Menu
- About
- For Research Patients
- Para Pacientes
- For Investigators
- For Industry Sponsors
- K-12 Programs
- Leadership Development
close
Please contact us for more information or to learn if you are eligible to participate.
To evaluate the effect of tildacerfont in reducing A4 in subjects with CAH over 12 weeks.
Principal Investigator | Surya N. Mulukutla, MD |
Co-PI | Luis Cantu Jr. |
Sponsor | Spruce Biosciences |
Type of Trial | Interventional |